Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Contrast Medium-induced Nephropathy Clear all
Completed Not applicable Interventional Results available

AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN

NCT01976299
View directory record Official record
Conditions
Contrast Induced Nephropathy (CIN)
Interventions
AVERT
Device
Lead sponsor
Osprey Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
37
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Phase 3 Interventional

Prevention of Contrast Renal Injury With Different Hydration Strategies

NCT01218828
View directory record Official record
Conditions
Contrast Medium-induced Nephropathy
Interventions
LVEDP -Based hydration strategy, Standard hydration
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of CXA-10 in Healthy Volunteers

NCT02127190
View directory record Official record
Conditions
Acute Kidney Injury (Nontraumatic)
Interventions
CXA-10 emulsion, Placebo
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 29, 2026, 9:47 AM EDT
Terminated Not applicable Interventional

Remote Ischemic Preconditioning to Prevent Contrast Nephropathy

NCT02674451
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Remote ischemic preconditioning
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 29, 2026, 9:47 AM EDT
Completed No phase listed Observational

Clinical Validation of the RENISCHEM L-FABP POC Assay

NCT04864847
View directory record Official record
Conditions
Acute Kidney Injury, Contrast-induced Nephropathy
Interventions
RENISCHEM L-FABP POC Test
Diagnostic Test
Lead sponsor
Hikari Dx, Inc.
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Chandler, Arizona • Concord, California • Clearwater, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 29, 2026, 9:47 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy

NCT01093131
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
Oral hydration, Oral sodium bicarbonate, Intravenous Hydration, Intravenous sodium bicarbonate
Other · Drug
Lead sponsor
The Western Pennsylvania Hospital
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 29, 2026, 9:47 AM EDT
Not listed Phase 4 Interventional

Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy

NCT00939913
View directory record Official record
Conditions
Nephropathy
Interventions
intravenous NAC, Placebo
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2009 · Synced Sep 29, 2026, 9:47 AM EDT
Terminated Phase 3 Interventional

Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Chronic Kidney Injury in Patients With Kidney Disease

NCT00930436
View directory record Official record
Conditions
Contrast Induced Kidney Injury.
Interventions
sodium bicarbonate
Drug
Lead sponsor
MD Scientific
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
17
States / cities
Kissimmee, Florida • St. Petersburg, Florida • Rome, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Phase 4 Interventional

Patients With Renal Impairment Undergoing CT

NCT00292487
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
Iopamidol 370 mgI/mL
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 29, 2026, 9:47 AM EDT
Terminated Phase 1 Interventional

Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure

NCT00575419
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
N-acetylcysteine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Phase 2 Interventional

Contrast Enhanced Ultrasound for Renal Obstruction

NCT05090800
View directory record Official record
Conditions
Kidney; Obstruction, Renal Obstruction
Interventions
Definity contrast during ultrasound
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 29, 2026, 9:47 AM EDT
Completed No phase listed Observational

Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization

NCT03305874
View directory record Official record
Conditions
Contrast-induced Nephropathy
Interventions
Exposure to CBCIN risk score
Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 29, 2026, 9:47 AM EDT
Completed No phase listed Observational Results available

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

NCT00744939
View directory record Official record
Conditions
Fibrosis, Kidney Failure, Renal Insufficiency
Interventions
Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 29, 2026, 9:47 AM EDT
Withdrawn Phase 4 Interventional

Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography

NCT00335101
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus
Interventions
Iodixanol, Ioversol, Iopromide
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2019 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Phase 3 Interventional

Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate

NCT00312117
View directory record Official record
Conditions
Contrast Induced Nephropathy, Kidney Diseases
Interventions
Sodium bicarbonate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Phase 2 Interventional

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

NCT05758896
View directory record Official record
Conditions
Contrast Induced Acute Kidney Injury
Interventions
Isuzinaxib (APX-115), Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 29, 2026, 9:47 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography

NCT00793182
View directory record Official record
Conditions
Renal Impairment
Interventions
Ioversol 320 mgI/mL, Iodixanol 320 mgI/mL
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 29, 2026, 9:47 AM EDT
Completed Not applicable Interventional

Remote Ischemic Preconditioning for Renal Protection in TAVI

NCT03347032
View directory record Official record
Conditions
Aortic Valve Stenosis, Renal Insufficiency, Contrast-induced Nephropathy
Interventions
Remote ischemic preconditioning, Control
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Sep 29, 2026, 9:47 AM EDT
Completed No phase listed Observational

Mehran 2.0 Risk Score for Prediction of CA-AKI After PCI

NCT05132062
View directory record Official record
Conditions
Contrast-induced Nephropathy
Interventions
Percutaneous Coronary Intervention
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
14,616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 29, 2026, 9:47 AM EDT
Recruiting Phase 2Phase 3 Interventional

Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial

NCT04982419
View directory record Official record
Conditions
Acute Kidney Injury, Heart Failure, Contrast Induced Nephropathy, Coronary Angiography, Percutaneous Coronary Intervention
Interventions
Remote ischemic preconditioning, Sham remote ischemic conditioning
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Dallas, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 29, 2026, 9:47 AM EDT